Latest Conference Coverage

Experts discussed gaps in LGS research, including biomarker development, sleep assessment, and early intervention strategies to improve diagnosis and outcomes for patients. [WATCH TIME: 6 minutes]

Experts underscored that stakeholder collaboration, including clinicians, caregivers, and industry partners, can play a critical role in advancing understanding and management of LGS. [WATCH TIME: 3 minutes]

Experts discussed initiatives to standardize data collection, expand registries, and empower families in advancing care for Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]

Experts highlighted the need for clearer treatment sequencing and improved transition of care for patients with LGS from childhood to adulthood. [WATCH TIME: 3 minutes]

The laureate professor at the University of Melbourne detailed the design and promising results of the PACIFIC trial of bexicaserin, an agent in development for epileptic encephalopathies. [WATCH TIME: 4 minutes]

The vice president of scientific engagement at the Alzheimer's Association discussed new data on amyloid-targeting therapies, expanded diagnostic tools, and emerging clinical guidelines for Alzheimer disease presented at AAIC 2025. [WATCH TIME: 5 minutes]

Amaal Starling, MD, FAHS, FAAN, associate professor of neurology at Mayo Clinic College of Medicine, shared data recently presented at AHS 2025 showing that eptinezumab extended the time between migraine attacks.

At AAIC 2025, the associate professor in the Department of Psychiatry at McGill University talked about the strengths and limitations of PET and blood biomarkers for Alzheimer disease. [WATCH TIME: 5 minutes]

The physician assistant specializing in Parkinson disease talked about the shared decision-making process when discussing advanced therapies for movement disorder care with patients. [WATCH TIME: 3 minutes]

The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 4th Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress.

At the 2025 ATMRD Congress, a patient advocate living with Parkinson disease emphasized the importance of amplifying patient voices at educational conferences for movement disorders. [WATCH TIME: 5 minutes]

Lea Grinberg, MD, PhD, a neuropathologist at Mayo Clinic Florida, discussed how tau accumulation and orexin neuron loss drive early sleep disturbances in Alzheimer disease and the potential for sleep-based biomarkers.

The headache neurologist at the Barrow Neurological Institute talked about an international expert panel that established agreed-upon definitions for refractory and resistant migraine. [WATCH TIME: 4 minutes]

At AHS 2025, the associate clinic director at the UC San Diego talked about the cautious use of cannabinoids in migraine and the importance of standard therapies before cannabinoids. [WATCH TIME: 3 minutes]

The director of the Brotman Facial Pain Clinic at the University of Maryland talked about emerging preclinical evidence supporting adenosine A3 receptor activation for post-traumatic trigeminal neuropathic pain. [WATCH TIME: 5 minutes]

At AHS 2025, Elizabeth Seng, PhD, professor of neurology at Albert Einstein College of Medicine, presented findings from a study showing that migraine was associated with increased odds of ischemic stroke in veterans.

The chief scientific officer at Alzheon talked about a symposium on the role of amyloid-beta oligomers in AD and phase 3 clinical data of valiltramiprosate presented at AAIC 2025. [WATCH TIME: 5 minutes]

The physician assistant specializing in Parkinson disease talked about how comorbidities and patient preference guide clinical decisions in prescribing on-demand therapies for Parkinson disease. [WATCH TIME: 5 minutes]

The CEO and cofounder of LSVT Global highlighted the importance of clinicians referring their patients with Parkinson disease early to evidence-based physical therapies, occupational therapies, and speech therapies. [WATCH TIME: 5 minutes]

At AAIC 2025, the founder and CEO at Veravas discussed the company’s VeraBIND tau pathology blood test, highlighting its potential to detect Alzheimer disease earlier with high accuracy. [WATCH TIME: 4 minutes]

At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emphasizing its potential role in early detection. [WATCH TIME: 4 minutes]

The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau antibody designed to slow or prevent the progression of AD. [WATCH TIME: 5 minutes]

At the 2025 ATMRD Congress, Anissa Mitchell, LCSW, chief program officer at PMD Alliance, discussed immersive, patient-focused sessions aimed at improving clinicians’ empathy, communication, and understanding of Parkinson disease and related disorders.

The medical director of CNS clinical cevelopment at AskBio discussed long-term data presented at ATMRD from the company’s phase 1b trial assessing the investigational gene therapy AB-1005 in Parkinson disease. [WATCH TIME: 6 minutes]

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the sleep disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.

At CMSC 2025, assistant professor of neurology at the University of California, San Francisco discussed progress on the integration of biomarkers into clinical practice for multiple sclerosis. [WATCH TIME: 4 minutes]

Researchers unveil promising findings from the GABriella trial, exploring a novel treatment for prodromal Alzheimer's disease at AAIC 2025.